EN
登录

Xentria在获得FDA反馈后推进XTMAB-16治疗肺结节病的临床开发

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback

CISION 等信源发布 2026-09-01 19:00

可切换为仅中文


XTMAB-16-201 Part A pharmacokinetic exposure, target-coverage, immunogenicity, safety and feasibility findings provided an integrated basis for further clinical evaluation and informed the proposed next-stage development plan

XTMAB-16-201 A部分药代动力学暴露、靶点覆盖、免疫原性、安全性和可行性研究结果为后续临床评价提供了综合依据,并为拟议的下一阶段开发计划提供了参考。

Proposed amendment to XTMAB-16-201 Part B will evaluate 4mg/kg every four weeks in a 52-week efficacy study called the XAtlas study

拟议的XTMAB-16-201第B部分修正案将在一项为期52周、名为XAtlas研究的疗效研究中评估每四周给予4mg/kg的方案。

CHICAGO

芝加哥

,

,

Sept. 1, 2026

2026年9月1日

/PRNewswire/ -- Xentria, Inc., a clinical-stage biotherapeutics company, today announced its proposed next-stage clinical development plan for XTMAB-16, an investigational anti-tumor necrosis factor alpha, being evaluated in pulmonary sarcoidosis, a rare disease for which no anti-TNFα is currently approved by the U.S.

/美通社/ -- 临床阶段生物治疗公司Xentria, Inc.今日宣布了其候选药物XTMAB-16的下一阶段临床开发计划。XTMAB-16是一种在研的抗肿瘤坏死因子α(anti-TNFα)药物,目前正用于评估治疗肺结节病,这是一种罕见疾病,目前美国尚未批准任何抗TNFα药物用于该适应症。

Food and Drug Administration..

食品药品监督管理局

Following an end-of-phase meeting, the FDA provided feedback on Xentria's proposed primary efficacy endpoint and overall trial design for

在阶段结束会议之后,美国食品药品监督管理局(FDA)就Xentria公司拟定的主要疗效终点及整体试验设计提供了反馈意见

Part B (XAtlas study)

B部分(XAtlas研究)

. Xentria plans to incorporate that feedback into an amendment to the ongoing XTMAB-16-201 protocol.

Xentria 计划将这些反馈意见纳入对正在进行的 XTMAB-16-201 方案的修订中。

Under the proposed design, planned enrollment for XAtlas would increase from 62 to up to 200 patients, and the study duration would extend to 52 weeks.

根据拟议的设计,XAtlas 的计划入组患者人数将从 62 名增加至最多 200 名,研究持续时间将延长至 52 周。

Xentria plans to evaluate XTMAB-16 at a dose of 4mg/kg administered every four weeks (Q4W). The proposed primary efficacy endpoint is change from baseline in forced vital capacity (FVC) with additional assessments expected to characterize disease control through measures, including the occurrence and timing of sarcoidosis worsening events, patient-reported reported respiratory outcomes and corticosteroid use..

Xentria 计划评估每四周一次(Q4W)给予 4 mg/kg 剂量的 XTMAB-16。拟议的主要疗效终点为用力肺活量(FVC)较基线的变化,并预计通过包括结节病恶化事件的发生及时间、患者报告的呼吸系统结局以及皮质类固醇使用情况在内的多项指标,对疾病控制情况进行进一步评估。

'Xentria is dedicated to pulmonary sarcoidosis,' said Tom Matthews, Senior Vice President of Clinical Development at Xentria. 'We are preparing operational activities with XAtlas enrollment planned in the fourth quarter of 2026.'

“Xentria 致力于肺结节病的研究,”Xentria 临床开发高级副总裁 Tom Matthews 表示。“我们正准备开展运营活动,计划于 2026 年第四季度启动 XAtlas 研究的受试者入组。”

Part A Study and Safety Highlights:

A部分 研究与安全重点:

XTMAB-16-201 Part A was a randomized, placebo-controlled, double-blind multiple ascending dose (MAD) trial in 39 adults with pulmonary sarcoidosis across the United States, European Union, and United Kingdom (38 completed). Patients received 2 mg/kg or 4 mg/kg administered every 2 or 4 weeks (Q2W or Q4W) during a 12-week period..

XTMAB-16-201 A部分是一项随机、安慰剂对照、双盲的多次递增剂量(MAD)试验,在美国、欧盟和英国共招募了39名肺结节病患者(38名完成试验)。患者在12周内每2周或每4周(Q2W或Q4W)接受2 mg/kg或4 mg/kg的给药。

Part A was designed to assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary clinical activity and to inform dose selection for further evaluation.

A部分旨在评估安全性、耐受性、药代动力学、免疫原性和初步临床活性,并为进一步评估的剂量选择提供依据。

Safety Profile:

安全概况:

XTMAB-16 was well tolerated with no unexpected treatment-emergent adverse events and no dose-limiting toxicities (DLTs) identified. In addition, no deaths, serious adverse events (SAEs) related to study intervention, opportunistic infections, lymphomas or hepatotoxicity were reported. Because of the study's limited sample size and duration, these observations do not establish the overall safety profile of XTMAB-16..

XTMAB-16 耐受性良好,未出现非预期的治疗期间不良事件,也未发现剂量限制性毒性(DLT)。此外,未报告与研究干预相关的死亡、严重不良事件(SAE)、机会性感染、淋巴瘤或肝毒性。由于本研究的样本量和持续时间有限,这些观察结果尚不能确立 XTMAB-16 的整体安全性特征。

Clinical and Biomarker Trends

临床与生物标志物趋势

:

:

Exploratory analysis identified numerical trends favoring XTMAB-16 versus placebo in corticosteroid tapering, lung function preservation and select patient-reported outcomes.

探索性分析发现,在皮质类固醇减量、肺功能维持以及部分患者报告结局方面,XTMAB-16 相较于安慰剂呈现出有利的数值趋势。

These exploratory findings are intended to inform the continued clinical development of XTMAB-16 as the study was not designed to establish efficacy for these outcomes.

这些探索性发现旨在为XTMAB-16的持续临床开发提供信息,因为本研究并非旨在确立这些结局指标的疗效。

Topline results

主要结果

from Part A were presented by Ogi Obi, M.D. at the American Thoracic Society International Conference in May 2026.

A部分的内容由Ogi Obi博士在2026年5月的美国胸科学会国际会议上发表。

'We appreciate the FDA's feedback on our proposed development plan,' said Tom Shea, CEO of Xentria. 'We plan to incorporate that feedback into the XAtlas protocol and move one step closer progressing XTMAB-16 in a disease of great unmet need.'

Xentria首席执行官Tom Shea表示:“我们感谢美国食品药品监督管理局(FDA)对我们拟议开发计划的反馈。我们计划将这些反馈纳入XAtlas方案中,从而在推进XTMAB-16用于存在巨大未满足需求的疾病领域方面更进一步。”

About Sarcoidosis

关于结节病

Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the formation of granulomas — clumps of inflammatory cells — in one or more organs in the body. Sarcoidosis affects people of all ages but most commonly affects young and middle-aged adults.

结节病是一种病因不明的慢性、多系统炎症性疾病,其特征是在身体的一个或多个器官中形成肉芽肿(即炎性细胞团块)。结节病可影响所有年龄段的人群,但最常见于青年和中年成年人。

While sarcoidosis can occur in any organ, more than 90% of patients with sarcoidosis will have the lungs affected, which is called pulmonary sarcoidosis. Left undiagnosed or untreated, the condition of patients with pulmonary sarcoidosis could degenerate into a chronic, progressive disease. Chronic, unresolved lung inflammation may result in scarring (fibrosis) that permanently damages the lung tissue and can lead to lung failure and death.

虽然结节病可累及任何器官,但超过90%的结节病患者会出现肺部受累,这被称为肺结节病。若未及时诊断或治疗,肺结节病患者的病情可能恶化为慢性、进展性疾病。长期未缓解的肺部炎症可能导致瘢痕形成(纤维化),从而对肺组织造成永久性损害,并可能引发肺衰竭甚至死亡。

In this complicated cascade of pro-inflammatory cytokines, the enhanced expression of TNFα, a cytokine that plays a significant role in antigen-stimulated, cell-mediated immune responses, may promote the formation of harmful granulomas and fibrosis throughout the body in people with sarcoidosis..

在这一复杂的促炎细胞因子级联反应中,TNFα(一种在抗原刺激和细胞介导的免疫反应中发挥重要作用的细胞因子)的表达增强,可能会促进结节病患者全身有害肉芽肿和纤维化的形成。

About XTMAB-16

关于XTMAB-16

XTMAB-16 is a chimeric human-murine anti-TNFα monoclonal antibody being developed as a novel biologic product for the treatment of pulmonary sarcoidosis with or without extra pulmonary involvement. Based on its ability to block TNFα, XTMAB-16 may disrupt an inflammatory pathway and help slow granuloma formation.

XTMAB-16 是一种人鼠嵌合抗 TNFα 单克隆抗体,正在开发为一种新型生物制剂,用于治疗伴有或不伴肺外受累的肺结节病。基于其阻断 TNFα 的能力,XTMAB-16 可能干扰炎症通路,并有助于减缓肉芽肿的形成。

Through dedicated regulatory work and focus from Xentria's team, XTMAB-16 was granted Orphan Drug Designation by the FDA for the New Drug Entity in November 2020. A Phase 1 clinical trial in healthy volunteers was completed in 2022. No TNFα inhibitor is currently approved for the treatment of sarcoidosis.

凭借Xentria团队在监管事务上的专注努力,XTMAB-16于2020年11月获得美国食品药品监督管理局(FDA)授予的新药实体孤儿药资格认定。一项在健康志愿者中开展的I期临床试验已于2022年完成。目前尚无肿瘤坏死因子α(TNFα)抑制剂获批用于结节病的治疗。

Extensive analyses have been conducted to demonstrate the physio-chemical properties and pharmacology of XTMAB-16 as a TNFα inhibitor. The clinical study of this effect remains ongoing..

已开展广泛分析,以证明XTMAB-16作为TNFα抑制剂的理化性质和药理学特征。针对该效应的临床研究仍在进行中。

About Xentria

关于Xentria

Established in 2020, Xentria works across biopharmaceutics communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from 'centrality', is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships.

Xentria 成立于2020年,活跃于生物制药领域,致力于建立创新且务实的协作与伙伴关系,以推动高难度药物的研发。Xentria 之名源于“中心性”(centrality),公司致力于通过有意义的患者参与和高效的合作伙伴关系,为雄心勃勃的药物创新提供定制化解决方案。

Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability..

总部位于芝加哥的Xentria正率先支持面向全球受众的生命科学倡议的蓬勃发展,同时培育多样性、个性化和可持续性。

To learn more about Xentria visit

欲了解更多关于Xentria的信息,请访问

www.xentria.com

www.xentria.com

.

。

SOURCE Xentria, Inc.

来源:Xentria 公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量,使用

Request a Demo

申请演示